Raily Aesthetic Medicine International Holdings Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Jianliang Song
Chief executive officer
CN¥933.0k
Total compensation
| CEO salary percentage | 96.5% |
| CEO tenure | 3yrs |
| CEO ownership | n/a |
| Management average tenure | 3.5yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Raily Aesthetic Medicine International Holdings Limited (HKG:2135) Held Back By Insufficient Growth Even After Shares Climb 37%
Oct 02
Benign Growth For Raily Aesthetic Medicine International Holdings Limited (HKG:2135) Underpins Its Share Price
Jul 22Revenues Working Against Raily Aesthetic Medicine International Holdings Limited's (HKG:2135) Share Price Following 47% Dive
Apr 22Raily Aesthetic Medicine International Holdings Limited (HKG:2135) Stock Rockets 39% As Investors Are Less Pessimistic Than Expected
Feb 07Raily Aesthetic Medicine International Holdings Limited's (HKG:2135) Popularity With Investors Is Under Threat From Overpricing
Dec 19Raily Aesthetic Medicine International Holdings Limited (HKG:2135) Investors Are Less Pessimistic Than Expected
Aug 22Statutory Profit Doesn't Reflect How Good Raily Aesthetic Medicine International Holdings' (HKG:2135) Earnings Are
Sep 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥32m |
| Mar 31 2024 | n/a | n/a | -CN¥32m |
| Dec 31 2023 | CN¥933k | CN¥900k | -CN¥32m |
| Sep 30 2023 | n/a | n/a | -CN¥26m |
| Jun 30 2023 | n/a | n/a | -CN¥20m |
| Mar 31 2023 | n/a | n/a | -CN¥18m |
| Dec 31 2022 | CN¥647k | CN¥600k | -CN¥16m |
| Sep 30 2022 | n/a | n/a | -CN¥13m |
| Jun 30 2022 | n/a | n/a | -CN¥11m |
| Mar 31 2022 | n/a | n/a | -CN¥14m |
| Dec 31 2021 | CN¥1m | CN¥1m | -CN¥18m |
| Sep 30 2021 | n/a | n/a | -CN¥3m |
| Jun 30 2021 | n/a | n/a | CN¥11m |
| Mar 31 2021 | n/a | n/a | CN¥8m |
| Dec 31 2020 | CN¥1m | CN¥1m | CN¥4m |
| Sep 30 2020 | n/a | n/a | -CN¥25k |
| Jun 30 2020 | n/a | n/a | -CN¥4m |
| Mar 31 2020 | n/a | n/a | CN¥3m |
| Dec 31 2019 | CN¥2m | CN¥2m | CN¥10m |
Compensation vs Market: Jianliang's total compensation ($USD127.83K) is below average for companies of similar size in the Hong Kong market ($USD230.88K).
Compensation vs Earnings: Jianliang's compensation has increased whilst the company is unprofitable.
CEO
Jianliang Song (68 yo)
3yrs
Tenure
CN¥933,000
Compensation
Mr. Jianliang Song serves as an Executive Director at Raily Aesthetic Medicine International Holdings Limited and serves as its Chief Executive Officer since December 28, 2021. Mr. Song is responsible for...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.9yrs | CN¥852.00k | 53.1% HK$ 31.9m | |
| CEO & Executive Director | 3yrs | CN¥933.00k | no data | |
| Chief Financial Officer | no data | CN¥433.00k | no data | |
| Executive Director | 3yrs | CN¥558.00k | no data | |
| Company Secretary | 4.1yrs | no data | no data |
3.5yrs
Average Tenure
47yo
Average Age
Experienced Management: 2135's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.9yrs | CN¥852.00k | 53.1% HK$ 31.9m | |
| CEO & Executive Director | no data | CN¥933.00k | no data | |
| Executive Director | 3yrs | CN¥558.00k | no data | |
| Independent Non-Executive Director | 4yrs | CN¥162.00k | no data | |
| Independent Non-Executive Director | 4yrs | CN¥162.00k | no data | |
| Independent Non-Executive Director | 4yrs | CN¥162.00k | no data |
4.0yrs
Average Tenure
48.5yo
Average Age
Experienced Board: 2135's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 22:34 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Raily Aesthetic Medicine International Holdings Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|